Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(66.7%)

Phase 2

1(33.3%)

3Total

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04456439Unknown

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Role: lead

NCT00702741Phase 1Completed

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

Role: lead

NCT00225095Phase 1Completed

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

Role: lead

NCT04366830Unknown

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Role: lead

NCT00081055Phase 2Withdrawn

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Role: lead

All 5 trials loaded